MSN2

2 papers2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

2 independent labs in 2 countries

Funders: H2020 European Research Council and 3 more

Cells2

Effects

Lifespan

upin yeast cells1

1 study

MSN2 improves lifespan in yeast cells.
“Together, this enables long-term survival in quiescence even in the absence of respiration”
Cellsin the absence of respiration
The environmental stress response regulates biophysics of the cytoplasm and survival in quiescence
The Journal of cell biology13 Mar 2026

Replicative lifespan

is required forin yeast cells1

1 study

MSN2 is required for replicative lifespan in yeast cells.
“We demonstrated that the observed increase in lifespan is dependent on MSN2 and autophagy pathways.”
Cellsin SUL1 deletion mutant
Deletion of sulfate transporter SUL1 extends yeast replicative lifespan via reduced PKA signaling instead of decreased sulfate uptake
eLife3 Sep 2025